There are plenty of diseases and conditions in the world, but cancer has the highest mortality rate. As a result of that, people are finding ways to keep them on the safe side. One of the ways of being on the safe side is by reading and researching about the killer disease. There are plenty of magazines and journals that give you all the information you need to know about various types of cancers and one good example is the Oncotarget. It is a weekly medical journal that covers all aspects of oncology including the prevention, diagnosis and even the treatment. The weekly publication was started in 2010 by the editors in Chief Mikhail and Andrei who are scientists. Therefore, you can be sure that you are getting information from experts. Impact Journals publish Oncotarget.
Oncotarget focuses on the basics of cancers and helps readers to learn about the top causes of the disease. Patients suffering from the condition are advised on the best and latest treatment and therapies through Oncotarget. Hence, it plays a huge role in the management of cancer. The Oncotarget helps people to learn how to lead healthy life styles so that they can have long and healthy lives. It also explores the current diagnosis, which helps scientists to come up with even better methods of tackling cancer. However, the main impact of Oncotarget is to make the most of the research on cancer by creating awareness to the readers.
Through the website, people get the platform to submit the information that they have on cancer as it offers an open platform.Today the journal is not dedicated to cancer only but in almost all areas of medicine. Due to the good work and positive impact, Oncotarget got the rank of the best journal from Thompson Reuter JCR impact factor in 2011. The best part is that it has maintained that till today. Another positive feature about the journal’s website is the fact that anyone can download and print the information that they want. It has archives in, which users can access all its journals since the year it was established.